- Home
- ADAP vs LRE Comparison
ADAP vs LRE Comparison
Compare ADAP & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- LRE
- Stock Information
- Founded
- ADAP 2008
- LRE 2001
- Country
- ADAP United Kingdom
- LRE Japan
- Employees
- ADAP N/A
- LRE N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- ADAP Health Care
- LRE
- Exchange
- ADAP Nasdaq
- LRE Nasdaq
- Market Cap
- ADAP 21.3M
- LRE 20.5M
- IPO Year
- ADAP 2015
- LRE 2023
- Fundamental
- Price
- ADAP $0.07
- LRE $2.15
- Analyst Decision
- ADAP Hold
- LRE
- Analyst Count
- ADAP 6
- LRE 0
- Target Price
- ADAP $1.02
- LRE N/A
- AVG Volume (30 Days)
- ADAP 63.5M
- LRE 2.2M
- Earning Date
- ADAP 11-12-2025
- LRE 07-30-2015
- Dividend Yield
- ADAP N/A
- LRE N/A
- EPS Growth
- ADAP N/A
- LRE N/A
- EPS
- ADAP N/A
- LRE N/A
- Revenue
- ADAP $65,084,999.00
- LRE $110,330,328.00
- Revenue This Year
- ADAP N/A
- LRE N/A
- Revenue Next Year
- ADAP $52.35
- LRE N/A
- P/E Ratio
- ADAP N/A
- LRE N/A
- Revenue Growth
- ADAP N/A
- LRE 3.92
- 52 Week Low
- ADAP $0.04
- LRE $1.00
- 52 Week High
- ADAP $1.12
- LRE $2.96
- Technical
- Relative Strength Index (RSI)
- ADAP 44.99
- LRE 73.22
- Support Level
- ADAP $0.06
- LRE $1.29
- Resistance Level
- ADAP $0.07
- LRE $1.44
- Average True Range (ATR)
- ADAP 0.01
- LRE 0.21
- MACD
- ADAP 0.01
- LRE 0.06
- Stochastic Oscillator
- ADAP 88.67
- LRE 58.38
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.